Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/09/26 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
  |
35 |
| 12/22/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
120 | |
| 12/16/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 12/10/25 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
|
180 |
| 12/02/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 12/02/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
19 | |
| 12/01/25 | 8-K | Current report |
|
|
2 |
| 11/26/25 | CORRESP | Correspondence |
|
1 | |
| 11/21/25 | 8-K | Current report |
|
|
5 |
| 11/04/25 | S-3 | Registration statement under Securities Act of 1933 |
|
|
39 |
